arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

VERTEX PHARMACEUTICALS INC / MA

VRTX
$542.75 ▼ -6.39 (-1.16%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
19 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
87
Health
Excellent
Bullish
auto_awesome

Analytical Summary

VERTEX PHARMACEUTICALS INC / MA shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $138.8B
Dividend Yield —
Revenue Growth 8.9% ↘
Op. Margin 34.8% ↗
ROIC 19.0% ↗
FCF / Share $12.49 ↗
Trailing P/E 35.1x
Price / Book 7.4x
FCF Yield 2.3%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$12.00B
↑ +8.9% —
Net Income Profit after all expenses
$3.95B
↑ +838.1% —
Operating Margin Operating profit as % of sales
34.8%
↑ +1745.4% 90th
FCF / Share Free cash flow per share
$12.49
↑ +507.6% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↓
91
Returns ↓
87
Financial Health ↑
97
Cash Quality ↓
54

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 19 years · 73 quarters